Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Coban
2. Monensin
3. Monensin A Sodium Complex
4. Monensin Monosodium Salt
5. Monensin-a-sodium Complex
6. Rumensin
1. Monensin Sodium Salt
2. 22373-78-0
3. Sodium Monensin
4. Monensin A Sodium Salt
5. Dsstox_cid_25573
6. Dsstox_rid_80970
7. Dsstox_gsid_45573
8. Nsc343257
9. Dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoate
10. C36h61nao11
11. Nsc-343257
12. Ncgc00017089-01
13. Sodium;(2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-ethyl-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-
14. Cas-22373-78-0
15. Mls002153986
16. Monensin Sodium 100 Microg/ml In Acetonitrile
17. Schembl4057708
18. Chembl1908308
19. Dtxsid2045573
20. Monensin Sodium Salt, 90% Min.
21. Hms2097e18
22. Hms3714e18
23. Hy-n0150
24. Tox21_110771
25. Tox21_113191
26. Mfcd00077826
27. S2324
28. Akos025147337
29. Am84797
30. As-0826
31. Ccg-220748
32. Smr001233320
33. Monensin Sodium 100 Microg/ml In Methanol
34. Cs-0007881
35. M2573
36. E78700
37. 2-[5-ethyltetrahydro-5-[tetrahydro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2h-pyran-2-yl]-2-furyl]-2-furyl]-9-hydroxy-?-methoxy-?,?,2,8-tetramethyl-1,6-dioxaspiro[4.5]decane-7-butyric Acid Sodium Salt
38. 4-[2-[5-ethyl-5-[5-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]- 3-methyloxolan-2-yl]oxolan-2-yl]- 9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]dec-7-yl]-3-methoxy-2-methylpentanoic Acid Sodium Salt
39. Sodium (2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2s,2'r,3's,5r,5'r)-2-ethyl-5'-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3'-methyl-[2,2'-bioxolan]-5-yl]-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-methoxy-2-methylpentanoate
40. Sodium;(2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-ethyl-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoate
Molecular Weight | 692.9 g/mol |
---|---|
Molecular Formula | C36H61NaO11 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 10 |
Exact Mass | 692.41115704 g/mol |
Monoisotopic Mass | 692.41115704 g/mol |
Topological Polar Surface Area | 156 Ų |
Heavy Atom Count | 48 |
Formal Charge | 0 |
Complexity | 1110 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 17 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
Antiprotozoal Agents
Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)
Coccidiostats
Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals. (See all compounds classified as Coccidiostats.)
Proton Ionophores
Chemical agents that increase the permeability of CELL MEMBRANES to PROTONS. (See all compounds classified as Proton Ionophores.)
Sodium Ionophores
Chemical agents that increase the permeability of CELL MEMBRANES to SODIUM ions. (See all compounds classified as Sodium Ionophores.)
Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
52
PharmaCompass offers a list of Monensin Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Monensin Sodium manufacturer or Monensin Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Monensin Sodium manufacturer or Monensin Sodium supplier.
PharmaCompass also assists you with knowing the Monensin Sodium API Price utilized in the formulation of products. Monensin Sodium API Price is not always fixed or binding as the Monensin Sodium Price is obtained through a variety of data sources. The Monensin Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Monensin Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Monensin Sodium, including repackagers and relabelers. The FDA regulates Monensin Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Monensin Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Monensin Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Monensin Sodium supplier is an individual or a company that provides Monensin Sodium active pharmaceutical ingredient (API) or Monensin Sodium finished formulations upon request. The Monensin Sodium suppliers may include Monensin Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Monensin Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Monensin Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Monensin Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Monensin Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Monensin Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Monensin Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Monensin Sodium suppliers with NDC on PharmaCompass.
Monensin Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Monensin Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Monensin Sodium GMP manufacturer or Monensin Sodium GMP API supplier for your needs.
A Monensin Sodium CoA (Certificate of Analysis) is a formal document that attests to Monensin Sodium's compliance with Monensin Sodium specifications and serves as a tool for batch-level quality control.
Monensin Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Monensin Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Monensin Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Monensin Sodium EP), Monensin Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Monensin Sodium USP).